Drugs / NY-ESO-1b peptide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00199836 | Sep 2003 → Sep 2005 | cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00066729 | Jun 2003 → May 2006 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1b peptide | “vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission.” PMID 18451240 ↗ May 2008 |
| Modality | Vaccine | “NY-ESO-1b peptide vaccine” NCT00066729 ↗ |
| Route | Subcutaneous | “Patients receive NY-ESO-1b peptide vaccine emulsified with Montanide® ISA-51 subcutaneously” NCT00066729 ↗ |